Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Splisense
company
About
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations.
- Jerusalem,Yerushalayim,Israel
- 1 - 10
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $28.50M
- Industries
- Biotechnology,Life Science,Pharmaceutical
- Founded date
- Jan 1, 2016
- Number Of Employee
- 1 - 10
- Operating Status
- Active
- Legal Name
- Splisense Ltd.
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$28.50M
Splisense has raised a total of
$28.50M
in funding over 2 rounds. Their latest funding was raised on
May 13, 2021 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 13, 2021 | Series B | $28.50M | 5 |
Cystic Fibrosis Foundation
|
— | Detail |
| Jan 1, 2016 | Seed | — | 1 |
Integra Holdings
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
5
Splisense is funded by 5 investors.
Cystic Fibrosis Foundation
and Biotel
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Cystic Fibrosis Foundation
|
Yes | Series B |
|
|
— | Series B |
|
Integra Holdings
|
— | Series B |
Israel Biotech Fund
|
— | Series B |
OrbiMed
|
— | Series B |
Employee Profiles
Number of Employee Profiles
3
Splisense has 3 current employee profiles, including
Executive Dr. Gili Hart
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
